Literature DB >> 25605897

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.

Marianne S Poruchynsky1, Edina Komlodi-Pasztor1, Shana Trostel1, Julia Wilkerson1, Marie Regairaz2, Yves Pommier2, Xu Zhang1, Tapan Kumar Maity1, Robert Robey2, Mauricio Burotto1, Dan Sackett3, Udayan Guha1, Antonio Tito Fojo4.   

Abstract

The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers. Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA). We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules. We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63. The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunoprecipitated with the microtubule motor dynein. Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels. We conclude DNA damage-repair proteins traffic on microtubules and addition of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.

Entities:  

Keywords:  DNA repair protein trafficking; DNA-damaging agents; combination chemotherapy; microtubule targeting agents; targeted therapies

Mesh:

Substances:

Year:  2015        PMID: 25605897      PMCID: PMC4321245          DOI: 10.1073/pnas.1416418112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

2.  Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.

Authors:  Robert F Murphy; Edina Komlodi-Pasztor; Robert Robey; Frank M Balis; Nicholas P Farrell; Tito Fojo
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

3.  Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

Authors:  Robert A Forrest; Lonnie P Swift; Ada Rephaeli; Abraham Nudelman; Ken-Ichi Kimura; Don R Phillips; Suzanne M Cutts
Journal:  Biochem Pharmacol       Date:  2012-03-05       Impact factor: 5.858

4.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

5.  Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics.

Authors:  Paraskevi Giannakakou; Michel Nakano; Kyriacos C Nicolaou; Aurora O'Brate; Jian Yu; Mikhail V Blagosklonny; Urs F Greber; Tito Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

Review 6.  Androgen receptor on the move: boarding the microtubule expressway to the nucleus.

Authors:  Maria Thadani-Mulero; David M Nanus; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2012-09-15       Impact factor: 12.701

7.  Natural history of early, localized prostate cancer: a final report from three decades of follow-up.

Authors:  Marcin Popiolek; Jennifer R Rider; Ove Andrén; Sven-Olof Andersson; Lars Holmberg; Hans-Olov Adami; Jan-Erik Johansson
Journal:  Eur Urol       Date:  2012-10-13       Impact factor: 20.096

8.  Ribosomal protein S3 localizes on the mitotic spindle and functions as a microtubule associated protein in mitosis.

Authors:  Chang-Young Jang; Hag Dong Kim; Xianghua Zhang; Jin-Soo Chang; Joon Kim
Journal:  Biochem Biophys Res Commun       Date:  2012-11-03       Impact factor: 3.575

Review 9.  Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Authors:  Andrew Eichholz; Roberta Ferraldeschi; Gerhardt Attard; Johann S de Bono
Journal:  Mol Cell Endocrinol       Date:  2011-10-01       Impact factor: 4.102

10.  The proliferation rate paradox in antimitotic chemotherapy.

Authors:  Timothy J Mitchison
Journal:  Mol Biol Cell       Date:  2012-01       Impact factor: 4.138

View more
  70 in total

Review 1.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

2.  Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.

Authors:  Agnes Basseville; Susan Bates; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2015-07-14       Impact factor: 66.675

Review 3.  Impact of DNA repair and stability defects on cortical development.

Authors:  Federico T Bianchi; Gaia E Berto; Ferdinando Di Cunto
Journal:  Cell Mol Life Sci       Date:  2018-08-16       Impact factor: 9.261

4.  Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.

Authors:  Christine G Skibinski; Tara Williamson; Gregory J Riggins
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

5.  High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.

Authors:  Bastien Gerby; Diogo F T Veiga; Jana Krosl; Sami Nourreddine; Julianne Ouellette; André Haman; Geneviève Lavoie; Iman Fares; Mathieu Tremblay; Véronique Litalien; Elizabeth Ottoni; Milena Kosic; Dominique Geoffrion; Joël Ryan; Paul S Maddox; Jalila Chagraoui; Anne Marinier; Josée Hébert; Guy Sauvageau; Benjamin H Kwok; Philippe P Roux; Trang Hoang
Journal:  J Clin Invest       Date:  2016-10-31       Impact factor: 14.808

6.  Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves.

Authors:  B M Cook; K M Wozniak; D A Proctor; R B Bromberg; Y Wu; B S Slusher; B A Littlefield; M A Jordan; L Wilson; Stuart C Feinstein
Journal:  Neurotox Res       Date:  2018-07-26       Impact factor: 3.911

7.  Centrobin plays a role in the cellular response to DNA damage.

Authors:  Na Mi Ryu; Jung Min Kim
Journal:  Cell Cycle       Date:  2019-08-15       Impact factor: 4.534

8.  Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells.

Authors:  Anisha Kothari; Walter N Hittelman; Timothy C Chambers
Journal:  Cancer Res       Date:  2016-05-06       Impact factor: 12.701

9.  Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Sarah J Benbow; Brett M Cook; Jack Reifert; Krystyna M Wozniak; Barbara S Slusher; Bruce A Littlefield; Leslie Wilson; Mary Ann Jordan; Stuart C Feinstein
Journal:  Neurotox Res       Date:  2015-12-11       Impact factor: 3.911

10.  Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.

Authors:  Andrew J Robles; Raushan T Kurmasheva; Abhik Bandyopadhyay; Doris A Phelps; Stephen W Erickson; Zhao Lai; Dias Kurmashev; Yidong Chen; Malcom A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2020-03-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.